Pediatric Meningococcal Vaccine's Approval Pathway May Work For Other Disease Areas
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA suggests serum bactericidal antibody measurements to predict protection from meningococcal diseases in children under age 2.
You may also be interested in...
Pfizer Anticipates Prevnar 13 For Older Adults Will Get Advisory Review In September
After the advisory committee, FDA would have one month to complete its review before the next ACIP meeting.
Pfizer Anticipates Prevnar 13 For Older Adults Will Get Advisory Review In September
After the advisory committee, FDA would have one month to complete its review before the next ACIP meeting.
Meningococcal Serogroup B Vaccines Can Be Approved With Surrogate Endpoints, FDA Says
Traditional placebo-controlled trials would require an impractically large patient population, the agency says as it seeks advisory committee input on post-marketing requirements.